Revelation Biosciences, Inc. (REVB)
NASDAQ: REVB · Real-Time Price · USD
4.118
-0.312 (-7.05%)
At close: Nov 4, 2026, 4:00 PM EST
3.895
-0.223 (-5.41%)
After-hours: Nov 4, 2026, 7:30 PM EST

Revelation Biosciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
6.095.014.434.515.495.04
Research & Development
5.184.063.554.155.386.91
Operating Expenses
11.279.077.988.6610.8611.95
Operating Income
-11.27-9.07-7.98-8.66-10.86-11.95
Other Non Operating Income (Expenses)
0.520.16-7.068.540.03-0.04
Pretax Income
-10.75-8.91-15.04-0.12-10.83-11.99
Net Income
-10.75-8.91-15.04-0.12-10.83-11.99
Preferred Dividends & Other Adjustments
8.455.95----
Net Income to Common
-19.2-14.87-15.04-0.12-10.83-11.99
Net Income Growth
------
Shares Outstanding (Basic)
00----
Shares Outstanding (Diluted)
00----
Shares Change
2741.09%-----
EPS (Basic)
-58.18-167.62----
EPS (Diluted)
-58.18-167.62----
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-9.44-8.27-18.34-7.29-11.22-11.22
Free Cash Flow Per Share
-28.60-93.25----
EBITDA
-11.24-9.04-7.95-8.63-10.84-11.93
D&A For EBITDA
0.030.030.030.030.030.02
EBIT
-11.27-9.07-7.98-8.66-10.86-11.95
SEC Filings: 10-K · 10-Q